Ryght AI and ElixirTrials have announced a strategic partnership aimed at bringing artificial intelligence-powered clinical trial workflows to research sites worldwide. The collaboration combines Ryght AI's global clinical research site intelligence and study startup capabilities with ElixirTrials' site-focused AI technology to help research teams manage trial activities more efficiently.

The initiative is expected to extend AI tools to Platinum-tier participants in Ryght's global site network, supporting workflows ranging from patient identification and screening to consent, monitoring, reporting, and trial management.

Combining Global Site Intelligence With AI-Powered Operations

Ryght AI uses its patent-pending AI Site Twins technology to create analytical models of clinical research sites, helping sponsors and contract research organizations identify locations that may be well suited to particular studies. The company says its network intelligence covers more than 330,000 research sites across 225 countries and territories.

ElixirTrials contributes its Cauldron operating system, which is designed to help research sites identify potentially eligible participants and coordinate clinical trial processes. The platform supports activities such as patient matching, screening, consent, enrollment, and ongoing trial operations through AI-enabled workflows integrated with electronic health record systems.

Together, the companies aim to connect site selection and study activation with the operational tools research teams need to carry out trials. The partnership is intended to help sites reduce administrative workloads while improving their ability to manage study requirements and participant journeys.

AI Tools Target Patient Identification and Trial Management

Under the proposed arrangement, Ryght AI plans to license ElixirTrials' site-facing AI technology and make its capabilities available through the Ryght platform.

The planned functionality covers several stages of clinical research, including:

• Patient pre-screening: Helping research teams identify individuals who may meet a study's eligibility criteria.

• Screening and consent: Supporting processes used to evaluate potential participants and document informed consent.

• Trial monitoring: Assisting with ongoing study activities and operational oversight.

• Reporting and administration: Reducing repetitive documentation and back-office tasks.

• Clinical trial management: Supporting workflows across the study lifecycle.

The companies intend to offer these capabilities as a benefit for sites participating in Ryght's Platinum-tier global study startup program. The approach is designed to give participating research sites access to practical automation tools without requiring them to independently assemble every component of an AI-enabled workflow.

Actual results will depend on implementation, site readiness, data quality, and the requirements of individual clinical studies.

Leadership Expertise to Support Global Study Startup

The collaboration also includes an advisory role for ElixirTrials CEO Heather Grey, who is expected to advise Ryght on global study startup operations.

The addition brings site-level operational experience into Ryght's broader effort to connect research sponsors with suitable trial locations and help those sites become operational more quickly.

For clinical research organizations, effective study startup involves more than selecting a location. Sites must also coordinate staffing, patient recruitment, documentation, regulatory requirements, and operational processes. Combining site intelligence with tools designed for day-to-day execution could help address some of these challenges.

Advancing AI Adoption Across Clinical Research

Clinical trials require coordination among sponsors, research sites, healthcare providers, and participants. Manual processes and fragmented systems can create operational burdens, particularly when studies involve multiple locations and complex eligibility requirements.

By combining global site intelligence with AI-assisted site workflows, Ryght AI and ElixirTrials aim to help research teams spend less time on repetitive administrative activities and more time supporting trial delivery and participant engagement.

The companies' next step is to negotiate a definitive licensing agreement in the coming months. The proposed agreement will determine the terms under which ElixirTrials' technology is integrated into Ryght's offering.

The partnership reflects a broader movement toward applying AI across the clinical research lifecycle, from identifying suitable research sites to supporting patient recruitment and study operations. Its impact will depend on how effectively the planned capabilities are integrated into existing clinical workflows while maintaining appropriate safeguards for patient privacy, data security, and research compliance.